Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Atara Biotherapeutics, Inc. (ATRA)
|
Add to portfolio |
|
|
|
| Price: |
$13.90
| | Metrics |
| OS: |
101.1
|
M
| |
-3914
|
% ROE
|
| Market cap: |
$1.41
|
B
| |
-228
|
% ROIC
|
|
Net cash:
|
$45.9
|
M
| |
$0.45
|
per share
|
|
EV:
|
$1.36
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($293)
|
M
| |
|
|
| EPS |
($2.79)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 31.0 | 272.5 | 0.0 | 282.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | -3.4% | | | | | | |
| Cost of goods sold | 0.0 | 209.0 | 0.0 | 360.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 31.0 | 63.6 | 0.0 | -78.8 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 23.3% | | -27.9% | | | | |
| Selling, general and administrative | 344.1 | | 360.8 | | 309.1 | | | |
| Research and development | | | | | | 216.1 | 167.5 | 81.2 |
| General and administrative | | 71.6 | | 78.8 | | 79.6 | 69.7 | 40.3 |
| EBIT | -262.9 | -330.8 | 0.0 | -340.5 | 0.0 | -295.7 | -237.1 | -121.5 |
| EBIT margin | -848.0% | -121.4% | | -120.7% | | | | |
| Pre-tax income | -228.3 | -228.3 | -340.1 | -340.1 | -306.6 | -291.0 | -230.7 | -119.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | | | | 0.0% | 0.0% |
| Net income | -228.3 | -228.3 | -340.1 | -340.1 | -306.6 | -291.0 | -230.7 | -119.5 |
| Net margin | -736.5% | -83.8% | | -120.6% | | | | |
| |
| Diluted EPS | ($2.24) | ($2.24) | ($3.63) | ($3.63) | ($4.15) | ($5.67) | ($5.27) | ($4.00) |
| Shares outstanding (diluted) | 102.0 | 102.0 | 93.7 | 93.7 | 74.0 | 51.3 | 43.8 | 29.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|